UCB is a global biopharmaceutical company, with a focus on neurology and immunology.
The key element of our evolution is to focus on the delivery of increased patient value. There is no such thing as an “average patient”. We want to use all the tools, channels and scientific advances at our disposal to develop a better understanding of the various expressions of a disease and embed the real needs of specific patient populations in our science and innovation process. Rather than starting researching any new drug with the science alone, we want to better connect patients with science and science with patients.
Better understanding the reality of patients living with neurological and immunological disorders will enable us to take a more holistic approach to care, ensuring that ultimately the right drug and the right care reaches the right patients in order for them to live the lives they choose.